Showing results (311-320 of 391) with videos related to

Sort By:
Pageof 40
Nature Communications|July 8, 2023
Global environmental implications of atmospheric methane removal through chlorine-mediated chemistry-climate interactionsQinyi Li, Daphne Meidan, Peter Hess, et al.
Annals of Neurology|November 5, 2003
Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315REsther van Herpen, Sonia M Rosso, Lies-Anne Serverijnen, et al.
European Urology|December 27, 2015
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell CarcinomaConstantijn H J Muselaers, Marye J Boers-Sonderen, Tim J van Oostenbrugge, et al.
Human Vaccines & Immunotherapeutics|May 22, 2015
Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigueHetty Prinsen, Hanneke W M van Laarhoven, Jeanette M Pots, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|January 17, 2012
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot studyI M E Desar, E G W ter Voert, Th Hambrock, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 13, 2021
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reportsM J M Uijen, Y H W Derks, R I J Merkx, et al.
International Journal of Cancer|January 11, 2021
The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposureStefanie D Krens, Floor J E Lubberman, Marthe van Egmond, et al.
Oncotarget|April 9, 2019
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanomaCarla M L van Herpen, Sanjiv S Agarwala, Axel Hauschild, et al.
Therapeutic Drug Monitoring|August 25, 2022
Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and ToxicityRien H L Hoge, Suzan E H Detert Oude Weme, Walter L Vervenne, et al.
The Oncologist|June 16, 2021
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid TumorsHui K Gan, Michael Millward, Mathilde Jalving, et al.
Pageof 40